ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Satcher Names CDC Director; POG Appoints Monaco To Data Monitoring Committee

September 10, 1993

Conferees Agree On $815 Million For NCI In ‘77

July 30, 1976

Decision Network Votes 14-11 for Laetrile Testing

September 29, 1978

ODAC Votes Against Cell Therapeutics Agent; Requires ChemGenex To Develop Diagnostic.

April 9, 2010

Stronger Federal Role Needed To Improve Palliative Care.

June 22, 2001

OMB Restriction On Reprogramming Threatens Grants Of Three Centers, Possible Restorations

June 6, 1986